Conference Coverage

Clinical Progress Reported for Anti-Tumor Drug AG337

Published in Cancer Weekly, April 10th, 1995

Agouron Pharmaceuticals, Inc., La Jolla, California, announced that results from Phase I clinical studies of the anti-cancer drug AG337 being developed by Agouron were reported in several presentations at the annual meeting of American Association of Cancer Research, held in Toronto, Ontario, Canada, March 17-22, 1995.

The Phase I studies carried out by clinical investigators in England concluded that AG337 was well tolerated up to doses that produced anti-tumor effects in several patients.

In one study, Dr. Hilary Calvert and colleagues at the University of Newcastle upon Tyne administered escalating doses of AG337 as a five-day infusion every three...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1995-04-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry